Ovarian Cancer Drug Given Fast-Track Approval

Rubraca’s use is specific to women with a mutation of the BRCA gene, FDA said (HealthDay News) — The anti-cancer drug Rubraca (rucaparib) has been granted accelerated approval by the U.S. Food and Drug Administration to treat advanced ovarian cancer. The approval is limited to cases where the cancer is caused by specific gene mutations…